Comparing Cerezyme vs Zavesca
| Cerezyme (imiglucerase) | Zavesca (miglustat) |
|
|---|
| Cerezyme (imiglucerase) | Zavesca (miglustat) |
|
|||||||
|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Gaucher Disease, Thrombocytopenia. Cerezyme may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Gaucher Disease. Zavesca may also be used for purposes not listed in this medication guide. |
Related suggestions Gaucher Disease
Popular comparisons
|
|||||||
| More about Cerezyme (imiglucerase) | More about Zavesca (miglustat) | ||||||||
| Ratings & Reviews | |||||||||
|
Cerezyme has an average rating of 9.0 out of 10 from a total of 1 ratings on Drugs.com. 100% of reviewers reported a positive effect, while 0% reported a negative effect. |
Be the first to share your experience with this drug. |
||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | |||||||||
|
View all Cerezyme side effects |
View all Zavesca side effects |
||||||||
| Drug Class | |||||||||
| Generic Availability | |||||||||
|
N/A |
|||||||||
| Pricing and Coupons * Prices are without insurance | |||||||||
|
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
View all Zavesca prices |
||||||||
| Dosage Forms | |||||||||
|
|
||||||||
| Brand Names | |||||||||
|
N/A |
Other miglustat brands include: Opfolda, Yargesa | ||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | |||||||||
|
0.17 hours |
7 hours |
||||||||
| CSA Schedule 1 View glossary of CSA terms | |||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||
| Pregnancy Category | |||||||||
|
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
||||||||
| Drug Interactions | |||||||||
|
A total of 1 drugs are known to interact with Cerezyme:
|
A total of 1 drugs are known to interact with Zavesca:
|
||||||||
| Alcohol/Food/Lifestyle Interactions | |||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
|
||||||||
| Disease Interactions | |||||||||
|
No known disease interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
|||||||||
| First Approval Date | |||||||||
|
May 23, 1994 |
July 31, 2003 |
||||||||
| WADA Class View classifications | |||||||||
|
N/A |
N/A |
||||||||
| More Information | |||||||||
| Patient Resources | |||||||||
| Professional Resources | |||||||||
| Related Treatment Guide | |||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
See also:
Decadron
Decadron is used for addison's disease, adrenal insufficiency, adrenocortical insufficiency ...
Dexamethasone Intensol
Dexamethasone Intensol is used for addison's disease, adrenal insufficiency, adrenocortical ...
Ozempic
Learn about Ozempic (semaglutide) for type 2 diabetes treatment, weight management, cardiovascular ...
Deltasone
Deltasone is used for acute lymphocytic leukemia, adrenocortical insufficiency, allergic reactions ...
Rituxan
Rituxan infusion is used to treat certain leukemias and lymphomas and some non-cancer conditions ...
Promacta
Promacta is used to prevent bleeding episodes in patients with chronic immune (idiopathic) ...
Rayos
Rayos (prednisone, delayed-release) is used to treat rheumatoid arthritis, polymyalgia rheumatica ...
Truxima
Truxima is used to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia, rheumatoid ...
Doptelet
Doptelet (avatrombopag) is used to treat thrombocytopenia in patients with chronic liver disease ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.